Today, it is widely accepted that cortical cholinergic denervation in the AD brain represents one of the earliest and most severe transmitter changes while drugs that boosting cholinergic system (e.g., by AChE inhibition) are widely used for mild/moderate AD patients. The gene discussed is ACHE; the disease is Alzheimer disease.